Market Overview

UPDATE: Citigroup Reduces PT to $49 on Teva Pharmaceuticals on Lower Estimates

Related TEVA
Teva Announces UK High Court Gives Positive Judgment In The Company's Patent Case Against AstraZeneca
Notable Hedge Funds Disclose Additions And Reductions To Holdings
Sofinnova Ventures Closes $500M Fund (Fox Business)

Citigroup reduces its price target fro $55 to $49 on Teva Pharmaceuticals (NASDAQ: TEVA) as it reiterates shares at Buy.

Citigroup notes, "We lowered our 2012E EPS on TEVA by (-$0.28) to $5.40 (+9%) compared to TEVA's rebased 2012E EPS range of $5.30(+7%)-$5.40(+9%) vs. the Street's $5.57 & below its previous $5.48 (+10%)-$5.68(+14%) on lower sales. Our 2012E sales decreased by (-$780M) to $20.5B vs. TEVA's $20.0B-$21.0B range. We lowered our 2013E & 2014E sales/EPS by (-$760M) & (-$790M) to $21.9B(+7%) & $23.2B(+6%) & (-$0.19) /( -$0.20) to $6.06(+12%)/$6.43 (+6%). Our 3-yr 2011-14E sales/EPS CAGR's decrease to +8%/+9% from +9%/ +10%."

TEVA closed at $38.69 on Thursday.

Latest Ratings for TEVA

DateFirmActionFromTo
Aug 2014UBSMaintainsNeutral
Jul 2014JP MorganMaintainsNeutral
Jul 2014BarclaysMaintainsOverweight

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

 

Related Articles (TEVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters